Leukemia: Present and Future
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 1040
Special Issue Editor
Special Issue Information
Dear Colleagues,
Leukemia is a malignant tumor of the blood originating from immature leukocytes (lymphoid and myeloid). It is the most common form of childhood cancer (~1/3 of cases) and accounts for >44,000 new diagnoses and >22,000 deaths each year worldwide. Leukemia occurs due to the malignant transformation of pluripotent hematopoietic stem cells (i.e., it can give rise to both myeloid and lymphoid precursors). Rarely, it can also involve a more busy stem cell with limited self-renewal capabilities. In acute leukemias, these malignant cells are usually immature, poorly differentiated leukocytes (blasts), which may be lymphoblasts or myeloblasts. These blasts can undergo clonal expansion and proliferation, leading to replacement and interference with normal blood cell development and function, leading to clinical symptoms. This Special Issue provides the opportunity to describe recent original research in the field of leukemia, as well as the development or application of new platforms or insights and/or reviews in the field. We are particularly interested in genomics and next generation sequencing (NGS), study of the mutations, leukemia stem cell research, new therapies, epidemiological studies and new biomarker studies, pregnancy, case clinical and COVID-vaccination.
Prof. Dr. Carla Di Stefano
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute lymphoblastic leukemia (ALL)
- chronic lymphocytic leukemia (CLL)
- acute myelogenous leukemia (AML)
- chronic myelogenous leukemia (CML)
- non-Hodgkin Lymphoma in children, adolescents and young adults
- Hodgkin lymphoma
